NCT03352037 is a NA clinical trial of PET scan in Pancreatic Cystic Neoplasms, sponsored by University Health Network, Toronto.

Who is sponsoring NCT03352037?

NCT03352037 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT03352037?

Interventions in NCT03352037: PET scan.

What condition does NCT03352037 study?

NCT03352037 studies Pancreatic Cystic Neoplasms.

Is NCT03352037 still recruiting?

NCT03352037 is currently completed. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT03352037

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study

Completed NA Last updated 19 April 2021

What this trial tests

NA trial testing PET scan in Pancreatic Cystic Neoplasms in 11 participants. Completed in 31 July 2018.

Timeline

15 June 2017

Primary endpoint
31 July 2018

31 July 2018

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	11
Start date	15 June 2017
Primary completion	31 July 2018
Estimated completion	31 July 2018
Sites	1 location across Canada

Drugs / interventions tested

PET scan — full drug profile →

Conditions studied

Pancreatic Cystic Neoplasms — all drugs for Pancreatic Cystic Neoplasms →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Pancreatic Cystic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overlap of morphological imaging features results in many incidentally detected pancreatic cystic neoplasms going undiagnosed, including benign serous cystic neoplasms (SCN) and potentially malignant mucinous lesions (nonserous). The diagnostic ambiguity then lead to invasive procedures such as endoscopic ultrasonography (EUS), unwarranted surgical resection on SCN lesions or the need for long term periodic surveillance with delayed diagnosis of potentially malignant nonserous lesions. Therefore, precise differentiation of SCN from nonserous cystic neoplasms is highly desirable. The 18F-fluorodeoxyglucose (FDG) accumulation in tumor cells, which is induced by high expression of glucose transporter proteins (mainly include GLUT-1 and -3), can be used to discriminate malignant and benign pancreatic cystic tumors in positron emission tomography (PET) imaging. GLUT-1 expression has also been documented in benign SCN while no such evidence exists in potentially malignant nonserous cystic neoplasms. Based on this evidence, investigators will conduct a pilot study to evaluate if integrated 18F-FDG PET/MR imaging with simultaneous MR and PET acquisition is helpful in differentiation of SCN from nonserous lesions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions.
Li J, Fu C, Zhao S, Pu Y, et al · · 2023 · cited 5× · PMID 37188192 · DOI 10.3389/fonc.2023.920896

Verify or expand the search:

Other trials of PET scan

Trials testing the same drug.

NCT07367815 — Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease · Phase 1, PHASE2 · not yet recruiting
NCT06398392 — Radiation Dosimetry of the 18 kDa Translocator Protein Ligand [18F]PBR111 in Humans · NA · completed
NCT05012098 — Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). · Phase 2 · completed
NCT04101968 — The GBA Multimodal Study in Parkinson's Disease · recruiting
NCT03554473 — M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers · Phase 1, PHASE2 · completed

Other recruiting trials for Pancreatic Cystic Neoplasms

Currently open trials in the same condition.

NCT07536087 — Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumor · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03352037 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03352037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing